Courtney DiNardo, MD, MSCE, clinical researcher in the Department of Leukemia of the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, presents promising results from the phase 3 VIALE-A trial. The trial uses a combination of venetoclax plus azacitidine for the treatment of acute myeloid leukemia (AML) in patients 75 years or older with comorbidities contraindicative of chemotherapy. At the median follow up, Dr. DiNardo reported a 14.7 month median overall survival (OS) for the venetoclax and azacitidine cohort versus 9.6 month median OS for the cohort receiving azacitidine and a placebo. Dr. DiNardo saw a complete response in 36.7% of patients receiving the combination versus 17.9% in the control group.
Click here for the full podcast transcript.